Yoshiji Hitoshi, Noguchi Ryuichi, Fukui Hiroshi
Third Department of Internal Medicine, Nara Medical University.
Nihon Rinsho. 2009 Apr;67(4):799-806.
Recent studies have shown that RAAS plays a pivotal role in the progression of chronic liver diseases, i.e., liver fibrosis and hepatocellular carcinoma (HCC). Many studies have demonstrated that the clinically used angiotensin-converting enzyme inhibitor (ACE I), and AT1-R blockers (ARB) significantly attenuated the liver fibrosis development and HCC. The combined treatment of ACE-I with other clinically used agents, such as interferon, imatinib mesylate, and vitamin K shows more potent inhibitory effects on the development of liver fibrosis and HCC. Since RAAS inhibitors are widely used in the clinical practice without serious side effects, they may represent a potential new therapeutic strategy against the progression of chronic liver diseases.
近期研究表明，肾素-血管紧张素-醛固酮系统（RAAS）在慢性肝病（即肝纤维化和肝细胞癌（HCC））的进展中起关键作用。许多研究已证明，临床使用的血管紧张素转换酶抑制剂（ACE I）和AT1受体阻滞剂（ARB）可显著减轻肝纤维化的发展及肝细胞癌的发生。ACE-I与其他临床使用的药物（如干扰素、甲磺酸伊马替尼和维生素K）联合治疗对肝纤维化和肝细胞癌的发展显示出更强的抑制作用。由于RAAS抑制剂在临床实践中广泛使用且无严重副作用，它们可能代表一种针对慢性肝病进展的潜在新治疗策略。
